Company Overview

Diagnos Inc. is a Canada‑based medical technology company operating in the healthcare diagnostics and digital health industries. The company focuses on the early detection and screening of eye diseases, particularly those related to retinal health, using advanced image analysis and artificial intelligence. Diagnos’ core value proposition is improving access to preventative eye care while reducing costs and clinical burden through automated diagnostic support tools.

The company’s primary revenue driver is its proprietary CARA retinal analysis platform, which analyzes retinal images to identify risk indicators for conditions such as diabetic retinopathy and age‑related macular degeneration. Diagnos serves eye care professionals, clinics, hospitals, and public health screening programs, with a strategic emphasis on large‑scale population screening. Founded in the late 1990s, the company originally focused on hardware‑based ophthalmic imaging and progressively evolved toward software‑driven, AI‑enabled diagnostics, aligning its strategy with the growing demand for scalable tele‑ophthalmology solutions.

Business Operations

Diagnos operates through a single integrated business focused on retinal screening software and diagnostic services, generating revenue via software licensing, service contracts, and screening programs. Its operations are structured around the development, validation, and commercialization of the CARA platform, which can be deployed in clinical, mobile, or remote screening environments. The company maintains research and development capabilities alongside commercialization and customer support functions.

The company conducts both domestic operations in Canada and international activities through distribution agreements and screening initiatives. Diagnos controls its proprietary algorithms, image processing software, and associated intellectual property. Its business model relies on collaborations with optometrists, ophthalmologists, healthcare systems, and screening partners, rather than direct ownership of clinical facilities.

Strategic Position & Investments

Diagnos’ strategic direction centers on expanding the adoption of AI‑assisted retinal screening as a frontline preventative healthcare tool. Growth initiatives include increasing deployment of the CARA platform in public health programs, pursuing regulatory acceptance in additional jurisdictions, and enhancing algorithm performance through clinical data validation. The company positions itself as a cost‑effective alternative to specialist‑only screening, particularly in underserved or high‑volume populations.

Rather than pursuing large acquisitions, Diagnos has historically emphasized organic development and strategic partnerships, including collaborations aimed at accessing international markets and large screening populations. The company is actively involved in the digital health and medical AI sector, with emerging focus areas including telemedicine integration and scalable cloud‑based diagnostic services. Public disclosures do not indicate material controlling investments in unrelated businesses; activity remains tightly aligned with ophthalmic diagnostics.

Geographic Footprint

Diagnos is headquartered in Canada, where it conducts corporate management, research, and core operations. The company has established a market presence across North America, while also engaging in screening projects and commercial partnerships in Asia and Latin America, reflecting its emphasis on high‑population regions with growing demand for preventative eye care.

Internationally, Diagnos’ influence is primarily operational and commercial rather than asset‑heavy, relying on local partners, distributors, and healthcare organizations. This approach allows the company to participate in global screening initiatives without maintaining extensive physical infrastructure outside its home market.

Leadership & Governance

Diagnos is led by a management team with experience in medical technology, finance, and healthcare commercialization, guiding the company’s transition toward AI‑driven diagnostics. Leadership emphasizes clinical validation, regulatory credibility, and long‑term adoption within public health systems rather than short‑term device sales.

Key executives include:

• André Larente – President & Chief Executive Officer
• Luc Vaillancourt – Chief Financial Officer
• Denis Larocque – Chairman of the Board

The leadership’s strategic vision focuses on positioning Diagnos as a trusted provider of early‑stage diagnostic intelligence, supporting healthcare systems in shifting from reactive treatment to preventative care.